Cargando…

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other onco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antonicelli, Alberto, Cafarotti, Stefano, Indini, Alice, Galli, Alessio, Russo, Andrea, Cesario, Alfredo, Lococo, Filippo Maria, Russo, Patrizia, Mainini, Alberto Franco, Bonifati, Luca Giuseppe, Nosotti, Mario, Santambrogio, Luigi, Margaritora, Stefano, Granone, Pierluigi Maria, Dutly, André Emanuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575628/ https://www.ncbi.nlm.nih.gov/pubmed/23423768 http://dx.doi.org/10.7150/ijms.4609

Ejemplares similares

Chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer patients: is it time for additional evidence?
por: Cafarotti, Stefano, et al.
Publicado: (2011)

Chest wall tumors and prosthetic reconstruction: A comparative analysis on functional outcome
por: Leuzzi, Giovanni, et al.
Publicado: (2015)

Rationale and clinical benefits of an intensive long-term pulmonary rehabilitation program after oesophagectomy: preliminary report
por: Lococo, Filippo, et al.
Publicado: (2012)

Soluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical Relevance
por: Maramotti, Sally, et al.
Publicado: (2016)

Systematic Identification of Oncogenic EGFR Interaction Partners
por: Petschnigg, Julia, et al.
Publicado: (2017)

EGFR(vIII): An Oncogene with Ambiguous Role
por: Rutkowska, Adrianna, et al.
Publicado: (2019)

EGFR transactivates RON to drive oncogenic crosstalk
por: Franco Nitta, Carolina, et al.
Publicado: (2021)

Which Is the Best Treatment in Recurrent Thymoma? A Systematic Review and Meta-Analysis
por: Chiappetta, Marco, et al.
Publicado: (2021)

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
por: Costa, Daniel B, et al.
Publicado: (2007)

Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2
por: Bae, Kieun, et al.
Publicado: (2022)

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
por: Greulich, Heidi, et al.
Publicado: (2005)

EGFRAP encodes a new negative regulator of the EGFR acting in both normal and oncogenic EGFR/Ras-driven tissue morphogenesis
por: Soler Beatty, Jennifer, et al.
Publicado: (2021)

EGFR mutations in sinonasal squamous tumors: oncogenic and therapeutic implications
por: Udager, Aaron M., et al.
Publicado: (2015)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
por: Russo, Alessandro, et al.
Publicado: (2019)

A view on EGFR-targeted therapies from the oncogene-addiction perspective
por: Perez, Rolando, et al.
Publicado: (2013)

EGFR-Targeted Photodynamic Therapy
por: Ulfo, Luca, et al.
Publicado: (2022)

WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer
por: Saloura, Vassiliki, et al.
Publicado: (2017)

Cigarette smoke enhances oncogene addiction to c‐MET and desensitizes EGFR‐expressing non‐small cell lung cancer to EGFR TKIs
por: Tu, Chih‐Yen, et al.
Publicado: (2018)

Prognostic Factors and Long-Term Survival in Locally Advanced NSCLC with Pathological Complete Response after Surgical Resection Following Neoadjuvant Therapy
por: Lococo, Filippo, et al.
Publicado: (2020)

Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma
por: Vita, Emanuele, et al.
Publicado: (2021)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
por: Russo, Alessandro, et al.
Publicado: (2015)

Posterior mediastinal melanoma causing severe dysphagia: A case report
por: Meacci, Elisa, et al.
Publicado: (2008)

Oncogenic signaling in amphiregulin and EGFR‐expressing PTEN‐null human breast cancer
por: Kappler, Christiana S., et al.
Publicado: (2014)

Specific Inhibition of Tumor Cells by Oncogenic EGFR Specific Silencing by RNA interference
por: Takahashi, Masaki, et al.
Publicado: (2013)

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells
por: McCann, Aidan P., et al.
Publicado: (2018)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
por: Iacovino, Marialucia, et al.
Publicado: (2020)

Activation of β-Catenin by Oncogenic PIK3CA and EGFR Promotes Resistance to Glucose Deprivation by Inducing a Strong Antioxidant Response
por: Cardone, Luca, et al.
Publicado: (2012)

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR
por: Peraldo-Neia, Caterina, et al.
Publicado: (2018)

Understanding EGFR heterogeneity in lung cancer
por: Passaro, Antonio, et al.
Publicado: (2020)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Is PET/CT Able to Predict Histology in Thymic Epithelial Tumours? A Narrative Review
por: Chiappetta, Marco, et al.
Publicado: (2022)

Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B
por: Cipriano, Rocky, et al.
Publicado: (2013)

EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth
por: Chabu, Chiswili, et al.
Publicado: (2017)

Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway
por: Yun, Un-Jung, et al.
Publicado: (2017)

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation
por: Serna-Blasco, Roberto, et al.
Publicado: (2022)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome–Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy
por: Cafarotti, Stefano
Publicado: (2020)

EGFR Signaling in Liver Diseases
por: Komposch, Karin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8t28j1tkfdd96bns74n8cgeq8v